Thiourea compounds or pharmaceutically acceptable salts thereof and their use as immunosuppressants
By designing and synthesizing new thiourea compounds as STING inhibitors, the problems of insufficient activity and side effects of existing STING inhibitors are solved, and effective inhibition and safe therapeutic effects on STING signaling pathways are achieved.
Patent Information
- Application Number
- CN202410476643.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-19
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-04-19
AI Technical Summary
The existing STING inhibitors have weak activity and have side effects, making it difficult to effectively treat autoimmune diseases and inflammation-related diseases related to STING.
A thiourea compound and its pharmaceutically acceptable salt were developed. By designing and synthesizing new thiourea compound structures, it is used as a small molecule inhibitor of STING protein to inhibit the activation of STING signaling pathway, improve the therapeutic effect and Reduce toxicity.
It has achieved effective inhibition of STING signaling pathway, has strong STING inhibitory activity, is safe, is simple and efficient, and can be used to prevent or treat STING-mediated diseases.
Smart Images

Figure CN118496135B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to a thiourea compound or a pharmaceutically acceptable salt thereof and application thereof as an immunosuppressant. Background Art
[0002] The stimulator of interferon genes (STING) is an important component of innate immunity that senses the endogenous activator cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) produced by the cytoplasmic double-stranded DNA (dsDNA) sensor cyclic GMP-AMP synthase (cGAS). After being activated by cGAMP, STING will translocate from the endoplasmic reticulum to the Golgi apparatus and further activate downstream pathways such as interferon regulatory factor 3 (IRF3) and nuclear factor-κB (NF-κB), ultimately inducing the production of type I interferons (IFN) and other cytokines. The important role of the STING signaling pathway in antiviral and anti-tumor immunity makes it a popular target for drug development. However, excessive or abnormal activation of the STING signaling pathway often causes autoimmune diseases (such as systemic lupus erythematosus) and inflammatory diseases. Therefore, the development of STING inhibitors has received increasing attention.
[0003] There are two main categories of known STING small molecule inhibitors: the nitrofuran compound C-170 can covalently bind to the 91st cysteine of human and mouse STING and inhibit the activation of the STING signaling pathway by inhibiting the palmitoylation of STING, but as an anti-inflammatory drug, C-170 is too toxic to normal cells, which is not conducive to its further development; another covalent inhibitor is H-151, which has the same mechanism of action as C-170, but its lack of drugability limits its application in clinical trials. Among the non-covalent STING small molecule inhibitors, the most representative is SN-011, which prevents the activation of the STING signaling pathway by occupying the binding pocket of the endogenous ligand cGAMP and STING, but due to the lack of a cocrystal structure, further structural optimization of SN011 is hindered.
[0004] The STING inhibitors reported so far generally have weak activity and certain side effects. Therefore, in order to better treat autoimmune diseases and inflammatory diseases related to STING, it is of great clinical value to develop better anti-inflammatory drugs targeting STING. Summary of the invention
[0005] The present invention provides a thiourea compound or a pharmaceutically acceptable salt thereof and use thereof as an immunosuppressant. The compound can be used as a small molecule inhibitor of the STING protein, and can be used alone or in combination with other drugs to improve the efficacy of existing drugs for treating inflammatory and autoimmune diseases and reduce toxicity.
[0006] In order to achieve the above object, the present invention provides a thiourea compound or a pharmaceutically acceptable salt thereof, having a structure shown in formula (I):
[0007]
[0008] Wherein n=1-2, R1 is a chain alkyl group or an unsubstituted, monosubstituted or polysubstituted benzene ring, and R2 is an unsubstituted, monosubstituted or polysubstituted benzene ring or an unsubstituted thiophene ring.
[0009] Preferably, when R1 is a benzene ring and there is a substituent on the benzene ring, the substituent is selected from any one of halogen, cyano, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyl;
[0010] When R1 is a chain alkyl group, it is isopropyl, isobutyl or an alkane group with a length of 2-7;
[0011] When R2 is a benzene ring and has a substituent, the substituent is selected from one or more of halogen, nitro, trifluoromethyl, amino, hydroxyl, and substituted or unsubstituted alkyl.
[0012] Preferably, the thiourea compound is specifically:
[0013]
[0014]
[0015]
[0016] The present invention also provides a use of the thiourea compound or a pharmaceutically acceptable salt thereof according to any of the above technical solutions in the preparation of a STING inhibitor drug.
[0017] The present invention also provides a STING inhibitor drug, which is prepared using the thiourea compound or a pharmaceutically acceptable salt thereof described in any of the above technical solutions.
[0018] Preferably, the thiourea compound or a pharmaceutically acceptable salt thereof is at least one of compounds S11 and S12.
[0019] The present invention also provides a use of the thiourea compound or a pharmaceutically acceptable salt thereof according to any of the above technical solutions in the preparation of a drug for preventing or treating STING-mediated diseases.
[0020] Preferably, the STING-mediated disease is selected from at least one of infectious diseases, inflammatory diseases and autoimmune diseases.
[0021] Preferably, the inflammatory disease is selected from at least one of metabolic inflammation-related diseases (such as atherosclerosis, non-alcoholic fatty liver disease, gout), musculoskeletal muscle inflammation (such as osteoarthritis, rheumatoid arthritis), and digestive system inflammation (colitis, enteritis).
[0022] Preferably, the autoimmune disease is selected from at least one of STING-associated vasculitis (SAVI) of infancy, systemic lupus erythematosus (SLE), and psoriasis.
[0023] The present invention also provides a drug for preventing or treating STING-mediated diseases, which is prepared by using the thiourea compound or a pharmaceutically acceptable salt thereof described in any of the above technical solutions.
[0024] Preferably, the thiourea compound or a pharmaceutically acceptable salt thereof is at least one of compounds S11 and S12.
[0025] Compared with the prior art, the advantages and positive effects of the present invention are:
[0026] The thiourea compounds obtained by reasonable design and synthesis of the present invention have novel structures, can be used as STING inhibitors, and have low cytotoxicity to normal cells, and can be used to prepare drugs that inhibit the activation of the STING signaling pathway and to prepare drugs for preventing or treating STING-mediated diseases. Compared with existing STING inhibitors, the thiourea compounds of the present invention have the characteristics of strong STING inhibitory activity, high safety, and a simple and efficient synthesis process. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 is a schematic diagram of the synthetic route of compounds S1-S15;
[0028] Figure 2 is a schematic diagram of the synthetic route of compounds S16-S19;
[0029] Figure 3 is a schematic diagram of the specific synthesis route of compound S1;
[0030] Figure 4 is a schematic diagram of the specific synthesis route of compound S16;
[0031] Figure 5 The effect diagram of compound S1-S19 on inhibiting the activation of STING downstream signaling pathway in THP1 cells (representative results were selected for display, and the quantitative results of protein imprint were analyzed by one-way ANOVA, n=3, *=P<0.05, ***=P<0.001, ns=no significant difference);
[0032] Figure 6is the effect diagram of compounds S11 and S12 in inhibiting the expression of downstream inflammatory factors after STING signal activation (using one-way ANOVA, n=3, ***=P<0.001);
[0033] Figure 7 It is a graph showing the cytotoxic effects of compounds S11, S12 and the positive control compound SN011 on normal human and mouse cells. DETAILED DESCRIPTION
[0034] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0035] The raw materials and equipment used in the specific embodiments of the present invention are all known products, which are obtained by purchasing commercial products. The following abbreviations (Table 1) may be used in this specification.
[0036] Table 1. Abbreviations
[0037] abbreviation meaning MeCN Acetonitrile NMI N-Methylimidazole DIPEA N,N-Diisopropylethylamine TCFH Tetramethylchlorouronium hexafluorophosphate DMF N,N-Dimethylformamide DCM Dichloromethane EA Ethyl acetate PE Petroleum ether DMSO Dimethyl sulfoxide TEA Triethylamine <![CDATA[B2(OH)4]]> Tetrahydroxydiboron TBSCl tert-Butyldimethylsilyl chloride Pd / C Palladium on Carbon <![CDATA[Et3N·3HF]]> Triethylamine trihydrofluoride <![CDATA[H2]]> hydrogen 4,4'-bipyridine 4,4'-Bipyridine h Hour min minute
[0038] The primer sequences used to detect the target genes are shown in Table 2 below.
[0039] Table 2. Primer sequence list
[0040]
[0041] The synthesis method of the compound in formula (I):
[0042] The synthetic routes of compounds S1-S15 are as follows Figure 1 shown.
[0043] Using commercially available compound 1 as raw material, the hydroxyl group is protected with TBSCl to obtain intermediate 2; intermediate 3 is then obtained through acylation reaction with commercially available compound 2A; intermediate 3 is reduced with hydrogen and palladium carbon to obtain intermediate 4 by nitro group reduction; then TBAF is used to remove the hydroxyl protecting group to obtain intermediate 5; finally, intermediate 5 is reacted with different types of commercially available isothiocyanates to obtain compounds S1-S15.
[0044] The synthetic routes of compounds S16-S19 are as follows Figure 2 shown.
[0045] Using commercially available compounds 1 and 1A as raw materials, thiourea is first generated to obtain intermediate 2; the nitro group is then reduced to obtain intermediate 3; the hydroxyl group is protected using TBSCl to obtain intermediate 4; intermediate 4 is reacted with commercially available raw material 4A through acylation to obtain intermediate 5; finally, the hydroxyl protecting group is removed to obtain compounds S16-S19.
[0046] The following is explained in conjunction with specific embodiments:
[0047] Example 1
[0048] N-(4-hydroxy-3-(3-(4-methoxyphenyl)thioureido)phenyl)-[1,1'-biphenyl]-4-carboxamide (compound S1), the synthetic route of which is as follows Figure 3 shown.
[0049]
[0050] In a 100 mL eggplant-shaped flask, compound 1 (4-amino-2-nitrophenol) (1.4 g, 9.2 mmol), imidazole (700 mg, 10.3 mmol), TBSCl (2 g, 13.3 mmol) and DCM (30 mL) were added in sequence, and the mixture was reacted at room temperature for 2 h. The solvent was evaporated, and water and EA were added for extraction three times. The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was evaporated to obtain a yellow solid compound 2 (2.3 g, yield 95%). 1 H NMR (500MHz, DMSO-d6) δ6.98(d,J=2.7Hz,1H),6.82(d,J=8.8Hz,1H),6.78(dd,J=8.8,2.8Hz,1H),5.26(s,2H),0.91(s,9H),0.13(s,6H). 13 C NMR (125MHz, DMSO-d6) δ143.83,142.03,138.43,123.07,120.51,108.71,25.87,18.22.ESI-MS: m / z 269.23[M+H] + .
[0051] Into a 100 mL eggplant-shaped flask, compound 2 (1.4 g, 5.2 mmol), compound 2A (4-phenylbenzoic acid) (1.02 g, 5.2 mmol), TCFH (2.9 g, 10.4 mmol) and DCM (30 mL) were added in sequence and reacted at room temperature for 5 h. A white solid precipitated, which was filtered off and washed with DCM (30 mL). The solid was dried to give a white solid product, compound 3 (1.9 g, yield 85%). 1H NMR(500MHz,DMSO-d6)δ9.97(s,1H),8.05-7.99(m,2H),7.82-7.79(m,2H),7.77-7.72(m,2H),7.53-7.47(m,2H),7. 44-7.40(m,1H),7.23(d,J=2.6Hz,1H),6.84(dd,J=8.6,2.6Hz,1H),6.64(d,J=8.5Hz,1H),0.98(s,9H),0.20(s,6H). 13 C NMR(125MHz,DMSO-d6)δ165.00,143.20,139.67,138.57,134.56,133.76,129.51,1 28.69,128.52,127.34,126.94,118.35,109.47,108.22,26.24,18.45.ESI-MS:m / z 449.18[M+H] + .
[0052] Into a 100 mL eggplant-shaped flask, compound 3 (1 g, 2.2 mmol), catalytic amount of Pd / C and methanol (25 mL) were added in sequence. The reaction was allowed to react at room temperature overnight under H2 protection. The reaction solution was filtered and the filtrate was evaporated to dryness to obtain a yellow solid product compound 4 (0.77 g, yield 82%), which was used directly in the next step without further purification.
[0053] Compound 4 (0.77 g, 1.8 mmol), Et3N·3HF (1 g, 6.3 mmol) and DCM (15 mL) were added to a 50 mL eggplant-shaped bottle and reacted at room temperature for 3 h. A solid precipitated and the reaction solution was filtered to obtain a brown-black solid product 5 (0.42 g, yield 75%), which was used directly in the next step without further purification.
[0054] Compound 5 (0.2 g, 0.6 mmol), compound 5A (4-methoxyphenyl isothiocyanate) (99 mg, 0.6 mmol), TEA (121 mg, 1.2 mmol) and acetone (20 mL) were added to a 50 mL eggplant-shaped flask and refluxed for 4 h. The solvent was evaporated and column chromatography (DCM: MeOH = 100:1) was performed to obtain a white solid product S1 (234 mg, yield 76%). 1H NMR (400MHz, DMSO-d6) δ10.11(s,1H),9.73(s,1H),9.62(s,1H),8.94(s,1H),8.23(s,1H),8.01(d,J=8.0Hz,2H),7.78(d,J=8.0 Hz,2H),7.72(d,J=7.6Hz,2H),7.50-7.40(m,3H),7.39-7.31(m,3H),6.89(d,J=8.3Hz,2H),6.82(d,J=8.7Hz,1H),3.72(s,3H). 13 C NMR (125MHz, DMSO-d6) δ179.76,165.39,156.98,146.64,144.72,143.28,139.60,134.29,132.68,131.74,130 .82,129.53,128.72,127.36,126.94,126.54,119.68,118.90,115.47,114.11,55.68.ESI-MS:m / z470.18[M+H] + .
[0055] Example 2
[0056] N-(3-(3-ethylthioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S2)
[0057]
[0058] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced with ethyl isothiocyanate to obtain compound S2 with a yield of 58%. 1 H NMR (400MHz, DMSO-d6) δ10.09(s,1H),9.52(s,1H),8.76(s,1H),8.09-7.98(m,3H),7.78(d,J=7.8Hz, 3H),7.72(d,J=7.6Hz,2H),7.52-7.33(m,4H),6.82(d,J=8.7Hz,1H),3.44(s,2H),1.14-1.03(m,3H). 13C NMR (125MHz, DMSO-d6) δ180.52,165.03,146.85,143.29,139.59,134.29,130.97,129. 51,128.71,128.55,127.34,126.97,119.04,118.78,115.72,39.18,14.74.ESI-MS:m / z 392.28[M+H] + .
[0059] Example 3
[0060] N-(3-(3-(4-(tert-butyl)phenyl)thioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S3)
[0061]
[0062] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 4-tert-butylphenyl isothiocyanate to prepare compound S3 with a yield of 65%. 1 H NMR (400MHz, DMSO-d6) δ10.12(s,1H),9.84(s,1H),9.64(s,1H),9.04(s,1H),8.25(s,1H),8.02(d,J=8.1Hz,2H),7.78(d ,J=8.2Hz,2H),7.72(d,J=7.6Hz,2H),7.44(dq,J=15.1Hz,6H),7.33(d,J=8.4Hz,2H),6.84(d,J=8.7Hz,1H),1.25(s,9H). 13 C NMR(100MHz,DMSO-d6)δ179.55,165.14,147.48,146.75,143.37,139.71,137.25,134.40,130 .94,129.59,128.86,127.45,127.04,125.71,124.06,34.68,31.73.ESI-MS:m / z496.23[M+H] + .
[0063] Example 4
[0064] N-(4-Hydroxy-3-(3-isopropylthioureido)phenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S4)
[0065]
[0066] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced with isopropylthioisocyanate to prepare compound S4 with a yield of 72%. 1 H NMR (400MHz, DMSO-d6) δ10.08(s,1H),9.54(s,1H),8.70(s,1H),8.18(s,1H),8.01(d,J=8.1Hz,2H),7.78(d,J=8.3Hz, 3H),7.72(d,J=7.7Hz,2H),7.47(s,2H),7.39(d,J=8.0Hz,2H),6.81(d,J=8.7Hz,1H),4.35(s,1H),1.17-1.09(m,6H). 13 CNMR(125MHz,DMSO-d6)δ179.55,165.01,143.26,139.60,134.29,130.77,129.51,128 .77,128.71,128.54,127.34,127.00,126.95,115.48,45.73,22.87,22.56.ESI-MS:m / z 406.18[M+H] + .
[0067] Example 5
[0068] N-(3-(3-(sec-butyl)thioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S5)
[0069]
[0070] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced with butyl isothiocyanate to prepare compound S5 with a yield of 69%. 1 H NMR (400MHz, DMSO-d6) δ9.98(s,1H),9.47(s,1H),8.62(s,1H),8.10(s,1H),7.90(d,J=8.0Hz,2H),7.64(dd,J=24.4,7.8Hz,5H),7.36(t,J=7.5Hz ,2H),7.27(t,J=6.9Hz,2H),6.70(d,J=8.7Hz,1H),4.12(s,1H),1.37(dd d,J=21.6,13.9,6.8Hz,2H),0.98(d,J=6.5Hz,3H),0.74(t,J=7.4Hz,3H). 13CNMR(125MHz,DMSO-d6)δ179.93,164.99,143.26,139.61,134.30,130.78,129.51,128.70 ,128.54,127.34,126.95,118.60,118.29,115.39,51.04,29.05,20.11,10.83.ESI-MS:m / z 420.20[M+H] + .
[0071] Example 6
[0072] N-(3-(3-Benzylthioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S6)
[0073]
[0074] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by benzyl isothiocyanate to prepare compound S6 with a yield of 76%. 1 H NMR (400MHz, DMSO-d6) δ10.17(s,1H),9.66(s,1H),9.07(s,1H),8.30(t,J=5. 7Hz,1H),8.14(s,1H),8.06(d,J=8.1Hz,2H),7.83(d,J=8.0Hz,2H),7.76(d,J =7.7Hz,2H),7.51(t,J=7.8Hz,3H),7.42(t,J=7.3Hz,1H),7.35(d,J=6.5Hz,4 H),7.26(dd,J=7.8,4.7Hz,1H),6.88(d,J=8.7Hz,1H),4.76(d,J=5.5Hz,2H). 13 C NMR (125MHz, DMSO-d6) δ181.33,165.01,147.19,143.29,139.60,134.29,130.99,129.51,128.85,128.78,128.7 0,128.55,127.83,127.68,127.53,127.35,127.25,126.98,126.38,119.76,119.41,119.05,115.74.ESI-MS:m / z 454.18[M+H] + .
[0075] Example 7
[0076] N-(4-Hydroxy-3-(3-phenylethylthioureido)phenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S7)
[0077]
[0078] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 2-isothiocyanatoethylbenzene to prepare compound S7 with a yield of 64%. 1 H NMR (400MHz, DMSO-d6) δ10.09(s,1H),9.52(s,1H),8.89(s,1H),8.02(d,J=8.5Hz,3H),7.79(d,J=8.3Hz,3H),7.72(d,J=7.6H z,2H),7.44(dt,J=26.9,7.8Hz,4H),7.24(dd,J=17.4,7.3Hz,5H),6.82(d,J=8.7Hz,1H),3.66(s,2H),2.84(d,J=8.4Hz,2H). 13 C NMR(125MHz,DMSO-d6)δ180.86,165.00,143.29,139.80,139.60,138.05,134.29,130.97,129.51,129.33,129.10,1 28.92,128.85,128.71,128.55,127.35,127.24,126.97,126.58,119.25,118.93,115.73,46.37,35.74.ESI-MS:m / z 468.19[M+H] + .
[0079] Example 8
[0080] N-(3-(3-(4-fluorobenzyl)thioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S8)
[0081]
[0082] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 4-fluorobenzyl isothiocyanate to prepare compound S8 with a yield of 64%. 1H NMR (400MHz, DMSO-d6) δ10.10(s,1H),9.56(s,1H),8.98(s,1H),8.19(s,1H),8.01(d,J=8.2Hz,3H),7.78(d,J=8.1Hz,2H ),7.72(d,J=7.7Hz,2H),7.50-7.43(m,3H),7.40-7.34(m,3H),7.13(d,J=8.9Hz,2H),6.83(d,J=8.7Hz,1H),4.69(s,2H). 13 C NMR(125MHz,DMSO-d6)δ181.24,164.99,162.58,147.31,143.29,139.59,135.90,134.27,131.02,129.83,1 29.77,129.52,128.70,128.56,127.35,126.98,119.48,119.17,115.77,115.42,115.26,46.93.ESI-MS:m / z 472.18[M+H] + .
[0083] Example 9
[0084] N-(3-(3-heptylthioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S9)
[0085]
[0086] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced with 1-heptyl isothiocyanate to prepare compound S9 with a yield of 67%. 1 H NMR (400MHz, DMSO-d6) δ9.94(s,1H),9.39(s,1H),8.63(s,1H),7.95(s,1H),7.85(d,J=8.2Hz,2H),7.61(d,J=8.2Hz,3H),7.58-7.52(m,2H),7.30( t,J=7.6Hz,2H),7.27-7.18(m,2H),6.65(d,J=8.7Hz,1H),3.25(q,J=6.5H z,2H),1.31(q,J=7.0Hz,2H),1.08(dq,J=14.0Hz,8H),0.70-0.62(m,3H). 13C NMR(100MHz,DMSO-d6)δ180.74,165.03,146.69,143.31,139.63,134.33,130.97,129.53,128.73,128.56,1 27.36,126.97,126.68,118.92,118.67,115.66,44.38,31.75,29.02,22.57,14.46.ESI-MS:m / z462.24[M+H] + .
[0087] Example 10
[0088] N-(4-Hydroxy-3-(3-(trifluoromethyl)benzyl)thioureido)phenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S10)
[0089]
[0090] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 1-(isothiocyanatomethyl)-3-(trifluoromethyl)benzene to obtain compound S10 with a yield of 71%. 1 H NMR (400MHz, DMSO-d6) δ10.16(s,1H),9.66(s,1H),9.15(s,1H),8.27(s,1H),8.04(t,J=8.0Hz,3H),7.83(d,J=8.1Hz,2H),7.78-7.74(m ,2H),7.72-7.65(m,2H),7.64-7.55(m,2H),7.51(dd,J=7.8Hz,3H),7.42(t,J=7.3Hz,1H),6.88(d,J=8.7Hz,1H),4.83(d,J=5.7Hz,2H). 13 C NMR (125MHz, DMSO-d6) δ181.48,165.00,143.30,141.46,139.59,134.27,131.86,131.12,129.62,129.51,128 .76,128.69,128.55,127.35,127.00,126.97,124.21,123.86,119.47,115.96,47.14.ESI-MS:m / z522.24[M+H] + .
[0091] Embodiment 11
[0092] N-(4-Hydroxy-3-(3-(4-methoxybenzyl)thioureido)phenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S11)
[0093]
[0094] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 4-methoxybenzyl isothiocyanate to prepare compound S11 with a yield of 71%. 1 H NMR (500MHz, DMSO-d6) δ10.14(s,1H),9.62(s,1H),8.97(s,1H),8.18(d,J=5.9Hz,1H),8.14(s,1H),8.06-8.02(m,2H),7.86-7.79(m,2H),7.78-7 .73(m,2H),7.55-7.45(m,3H),7.45-7.39(m,1H),7.32-7.26(m,2H),6.9 3-6.86(m,2H),6.85(d,J=8.7Hz,1H),4.66(d,J=5.5Hz,2H),3.73(s,3H). 13 C NMR(125MHz,DMSO-d6)δ181.05,165.00,158.74,147.01,143.28,139.60,134.29,131.38,130.95,129.51,1 29.31,128.71,128.55,127.35,126.96,126.47,119.28,118.93,115.66,114.10,55.52,47.24.ESI-MS:m / z 484.18[M+H] + .
[0095] Example 12
[0096] N-(3-(3-(3,4-dichlorophenyl)thioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S12)
[0097]
[0098] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced with 3,4-dichlorobenzyl isothiocyanate to prepare compound S12 with a yield of 62%. 1H NMR (500MHz, DMSO-d6) δ10.15(s,1H),9.66(d,J=7.6Hz,1H),9.15(s,1H),8.19(s,1H),8.04(d,J=8.1Hz,2H),7.82(d,J=8.1Hz,2H),7.75(d,J=7.3Hz ,2H),7.71-7.66(m,2H),7.61-7.56(m,2H),7.54-7.49(m,3H),7.42(d,J=7 .7Hz,1H),7.33(dd,J=8.3,1.9Hz,1H),6.88(d,J=8.8Hz,1H),4.96(s,2H). 13 C NMR(125MHz,DMSO-d6)δ181.41,165.00,143.31,139.59,136.26,134.26,131.79,131.53,131.33,131.17,1 30.71,129.87,129.63,129.51,128.70,128.55,128.10,127.35,126.97,119.56,116.02,47.28.ESI-MS:m / z 522.10[M+H] + .
[0099] Embodiment 13
[0100] N-(3-(3-Hexylthioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S13)
[0101]
[0102] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 1-isothiocyanatohexyl ester to prepare compound S13 with a yield of 64%. 1 H NMR(400MHz,DMSO-d6)δ9.96(s,1H),9.41(s,1H),8.66(s,1H),7.97(s,1H), 7.88(d,J=8.0Hz,2H),7.65(d,J=8.1Hz,3H),7.59(d,J=7.6Hz,2H),7.34(t,J =7.5Hz,2H),7.26(q,J=8.1,7.5Hz,2H),6.68(d,J=8.7Hz,1H),3.28(q,J=7.1 ,6.6Hz,2H),1.34(q,J=7.0Hz,2H),1.12(d,J=7.7Hz,6H),0.76-0.65(m,3H). 13C NMR (125MHz, DMSO-d6) δ180.70,164.99,146.65,143.27,139.60,134.29,130.92,129.51,128.70,12 8.54,127.34,126.95,118.90,118.63,115.61,44.37,31.52,28.99,26.57,22.55,14.42.ESI-MS:m / z 448.21[M+H] + .
[0103] Embodiment 14
[0104] N-(3-(3-butylthioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S14)
[0105]
[0106] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 1-butyl isothiocyanate to prepare compound S14 with a yield of 62%. 1 H NMR(500MHz,DMSO-d6)δ10.13(s,1H),9.59(s,1H),8.84(s,1H),8.14(s,1H) ,8.08-8.01(m,2H),7.85(s,1H),7.83-7.79(m,2H),7.77-7.73(m,2H),7.50( dd,J=8.4,7.0Hz,2H),7.46-7.39(m,2H),6.85(d,J=8.7Hz,1H),3.45(q,J=6. 7Hz, 2H), 1.51 (p, J = 7.2Hz, 2H), 1.32 (h, J = 7.4Hz, 2H), 0.90 (t, J = 7.3Hz, 3H). 13 C NMR(125MHz,DMSO-d6)δ180.72,165.00,146.66,143.27,139.60,134.30,130.92,129.51,128.71,12 8.54,127.34,126.96,118.90,118.62,115.62,44.04,31.17,20.07,14.24.ESI-MS:m / z420.22[M+H] + .
[0107] Embodiment 15
[0108] N-(3-(3-heptylthioureido)-4-hydroxyphenyl)-4-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide (Compound S15)
[0109]
[0110] Referring to the method of Example 1, 4-methoxyphenyl isothiocyanate was replaced by 1-heptyl isothiocyanate, and 4-phenylbenzoic acid was replaced by 4'-trifluoromethyl-diphenyl-4-carboxylic acid to prepare compound S15 with a yield of 69%. 1 H NMR(500MHz,DMSO-d6)δ10.17(s,1H),9.60(s,1H),8.83(s,1H),8.14(s,1 H),8.10-8.07(m,2H),7.98(d,J=8.1Hz,2H),7.92-7.88(m,2H),7.85(d,J= 8.2Hz,3H),7.44(dd,J=8.8,2.6Hz,1H),6.84(d,J=8.7Hz,1H),3.51-3.39 (m,2H),1.55-1.47(m,2H),1.32-1.24(m,8H),0.85(td,J=6.9,1.7Hz,3H). 13 CNMR(125MHz,DMSO-d6)δ164.81,143.61,141.60,135.23,130.82,128.83,128.20,1 27.41,126.32,115.60,45.15,31.73,29.66,29.02,26.86,22.55,14.44.ESI-MS:m / z 530.23[M+H] + .
[0111] Example 16
[0112] N-(3-(3-(4-fluorobenzyl)thioureido)-4-hydroxyphenyl)-4-nitro-[1,1'-biphenyl]-4-carboxamide (Compound S16), the synthetic route of which is as follows Figure 4 shown.
[0113]
[0114] In a 100 mL eggplant-shaped flask, compound 1 (2-amino-4-nitrophenol) (1.4 g, 9.2 mmol), compound 1A (4-fluorobenzyl isothiocyanate) (1.5 g, 9.2 mmol), TEA (1.4 g, 13.8 mmol) and acetone (30 mL) were added in sequence, and the reaction was refluxed for 4 h. The solvent was evaporated and column chromatography (DCM:MeOH=100:1) was performed to obtain a yellow solid product 2 (2.5 g, yield 85%). 1 H NMR(500MHz,DMSO-d6)δ8.89(s,1H),8.72(s,1H),8.05(s,1H),7.41-7.31(m,2H),7.18-7.08( m,2H),6.94(s,1H),6.60(d,J=8.5Hz,1H),6.30(dd,J=8.5,2.7Hz,1H),4.68(d,J=5.7Hz,2H). 13 C NMR(125MHz,DMSO-d6)δ180.75,162.76,141.73,140.66,135.93,129.79,129.72,126.64 ,116.92,115.39,115.22,112.84,112.55,46.90,36.25,31.22.ESI-MS:m / z322.11[M+H] + .
[0115] In a 100 mL eggplant-shaped flask, compound 2 (500 mg, 1.6 mmol), catalytic amount of 4,4'-bipyridine, B2(OH)4 (416 mg, 4.8 mmol) and DMF (30 mL) were added in sequence and reacted at room temperature for 10 min. Water (50 mL) was added to precipitate a solid, which was filtered to obtain product 3 with a yield of 72%. The product was directly used for the next step without further purification.
[0116] Into a 100 mL eggplant-shaped flask, compound 3 (300 mg, 0.97 mmol), imidazole (136 mg, 2.0 mmol), TBSCl (0.3 g, 2.0 mmol) and DCM (20 mL) were added in sequence, and the reaction was carried out at room temperature for 2 h. The solvent was evaporated, and water and EA were added for extraction three times. The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was evaporated to obtain a light yellow solid compound 4 (384 mg, yield 92%). 1H NMR(500MHz,Chloroform-d)δ9.08(s,1H),7.38(dd,J=6.8,5.6,1.1Hz,2H),7.33(s,1H),7.19-7.11(m,2H),6.70(d,J=7.5Hz,1H ), 6.53 (d, J = 2.0Hz, 1H), 6.36 (dd, J = 7.5, 2.0Hz, 1H), 4.55 (s, 1H), 4.55 (d, J = 2.1Hz, 1H), 4.04 (s, 2H), 0.98 (s, 9H), 0.21 (s, 6H). 13 C NMR(125MHz,Chloroform-d)δ180.42,145.81,139.15,129.76,129.70,128.2 0,117.33,115.37,115.21,113.46,107.20,49.56,25.58,18.38.ESI-MS:m / z 406.20[M+H] + .
[0117] In a 100 mL eggplant-shaped flask, compound 4 (200 mg, 0.49 mmol), TCFH (277 mg, 1.0 mmol), 4'-nitro-[1,1'-biphenyl]-4-carboxylic acid (120 mg, 0.49 mmol), NMI (88 mg, 1.0 mmol) and MeOH (20 mL) were added in sequence and reacted at room temperature for 4 h. The solvent was evaporated and column chromatography (PE:EA=2:1) was performed to obtain a light yellow solid product 5, which was directly carried out to the next step without further purification.
[0118] Compound 5 (100 mg, 0.2 mmol), Et3N·3HF (100 mg, 0.6 mmol) and DCM (10 mL) were added in sequence to a 50 mL eggplant-shaped flask, and the mixture was reacted at room temperature for 2 h. The solvent was evaporated and the mixture was extracted three times with water and EA. The organic phases were combined and dried over anhydrous magnesium sulfate. The solvent was evaporated to give a yellow solid product S16 (38 mg, yield 47%). 1 H NMR (400MHz, DMSO-d6) δ10.05(s,1H),9.53(d,J=16.6Hz,1H),8.89(s,1H),8.20-8.16(m,2H),7.96-7.87(m,6H),7.79(q,J=5. 2,3.7Hz,2H),7.33(dd,J=8.7,2.6Hz,1H),7.27-7.20(m,2H),7.03-6.95(m,2H),6.70(d,J=8.7Hz,1H),4.56(d,J=5.4Hz,2H). 13C NMR(125MHz,DMSO-d6)δ164.71,162.58,160.66,147.48,145.98,140.82,135.67,130.88,129.84,129.7 7,128.90,128.64,127.88,127.69,124.64,119.44,119.15,115.75,115.43,115.26,46.91.ESI-MS:m / z 517.18[M+H] + .
[0119] Embodiment 17
[0120] N-(3-(3-(4-fluorobenzyl)thioureido)-4-hydroxyphenyl)-4-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxamide (Compound S17)
[0121]
[0122] Referring to the method of Example 16, 4'-nitro-[1,1'-biphenyl]-4-carboxylic acid was replaced with 4'-trifluoromethyl-diphenyl-4-carboxylic acid to obtain compound S17 with a yield of 52%. 1 H NMR (500MHz, DMSO-d6) δ10.19(s,1H),9.65(s,1H),9.03(s,1H),8.23(s,1H),8.08(d,J=7.8Hz,3H),7.98(d,J=7.7Hz,2H),7.88 (dd,J=20.5,7.9Hz,4H),7.48(d,J=8.9Hz,1H),7.39(t,J=6.9Hz,2H),7.15(t,J=8.9Hz,2H),6.86(d,J=8.6Hz,1H),4.71(s,2H). 13 C NMR(125MHz,DMSO-d6)δ181.25,164.82,162.58,160.66,143.61,141.62,135.87,135.21,130.93,1 29.80,128.83,128.21,127.44,126.34,119.46,119.15,115.76,115.43,115.26,46.92.ESI-MS:m / z 540.18[M+H] + .
[0123] Embodiment 18
[0124] 4'-Butyl-N-(3-(3-(4-fluorobenzyl)thioureido)-4-hydroxyphenyl)-[1,1'-biphenyl]-4-carboxamide (Compound S18)
[0125]
[0126] Referring to the method of Example 16, 4'-nitro-[1,1'-biphenyl]-4-carboxylic acid was replaced with 4-n-butylbiphenyl-4'-carboxylic acid to prepare compound S18 with a yield of 53%. 1 H NMR (400MHz, DMSO-d6) δ10.27(s,1H),9.74(s,1H),9.17(s,1H),8.42(s,1H),8. 15(d,J=8.0Hz,3H),8.03(d,J=8.1Hz,2H),7.92(dd,J=17.0,8.2Hz,5H),7.48-7 .42(m,2H),7.24-7.16(m,2H),6.94(d,J=8.7Hz,1H),4.77(d,J=5.5Hz,2H),3.2 7-3.13(m,2H),1.70-1.53(m,2H),1.34(h,J=7.3Hz,2H),0.97(t,J=7.3Hz,3H). 13 C NMR (100MHz, DMSO-d6) δ181.33,164.85,147.37,143.65,141.65,135.89,135.25,130.94,129.87,129.79,128.94,128 .87,128.24,127.45,126.36,119.49,119.18,115.83,115.47,115.26,57.98,46.93,23.53,19.69,13.97.ESI-MS:m / z 528.31[M+H] + .
[0127] Embodiment 19
[0128] N-(3-(3-(4-fluorobenzyl)thioureido)-4-hydroxyphenyl)-4-(thiophen-2-yl)benzamide (Compound S19)
[0129]
[0130] Referring to the method of Example 16, 4'-nitro-[1,1'-biphenyl]-4-carboxylic acid was replaced with 4-(2-thienyl)benzoic acid to prepare compound S19 with a yield of 49%. 1H NMR(400MHz,DMSO-d6)δ10.13(s,1H),9.64(s,1H),9.04(s,1H),8.24(s, 1H),8.07(s,1H),8.02-7.96(m,2H),7.86-7.79(m,2H),7.66(dd,J=13.1, 4.4,1.2Hz,2H),7.47(dd,J=8.7,2.6Hz,1H),7.43-7.35(m,2H),7.23-7.1 8(m,2H),7.18-7.13(m,1H),6.86(d,J=8.7Hz,1H),4.72(d,J=5.6Hz,2H). 13 C NMR(125MHz,DMSO-d6)δ180.42,165.98,163.17,161.15,147.79,143.09,138.91,138.13,135.15,133.0 3,129.73,128.10,127.69,127.03,126.75,125.84,124.62,116.94,115.36,115.21,49.56.ESI-MS:m / z 478.21[M+H] + .
[0131] Embodiment 20
[0132] Inhibitory effects of compounds S1-S19 of the present invention on the STING downstream signaling pathway
[0133] The STING agonist SR717 activates the STING signaling pathway in THP1 cells and promotes the phosphorylation of downstream TANK binding kinase 1 (TBK1). Therefore, the expression of phosphorylated TBK1 protein in cells was detected by western blot technology to determine the inhibitory effect of compounds S1-S19 on the STING downstream signaling pathway. ImageJ software was used to quantify the protein blot and draw a bar graph for activity comparison.
[0134] In THP1 cells, the STING agonist SR717 treatment group was used as a control, the DMSO group was used as a blank control, and the STING inhibitor SN011 was used as a positive control. Compounds S1-S19 (3 μM) and SN011 (3 μM) were first added to pretreat the cells for 1 hour, and then SR717 (20 μM) was added to activate the STING signaling pathway. After 4 hours, the cells were lysed with RIPA lysis buffer, and the protein was extracted. The protein concentration was determined by the Bradford method, and SDS-PAGE was run. Under the premise that the internal reference expression level was the same, the strength of the phosphorylated TBK1 band was used to preliminarily judge the ability of the compound to inhibit the activation of the STING signaling pathway.
[0135] The experimental results are as follows Figure 5 As shown, the compounds S8-S13 and S15-S17 of the present invention almost completely inhibited the promotion of TBK1 phosphorylation by the STING agonist SR717 at a concentration of 3 μM. According to the quantitative results of ImageJ, the inhibitory activity of S8 and S9 is comparable to that of the positive control SN011, while the inhibitory activity of S11, S12, and S17 is superior to that of the positive control SN011. This shows that compounds S8-S13 and S15-S17 can significantly inhibit the activation of the STING downstream signaling pathway, and have the potential to be developed as STING inhibitors and treat STING-mediated diseases.
[0136] Embodiment 21
[0137] Inhibitory effects of compounds S11 and S12 of the present invention on downstream inflammatory factors of the STING signaling pathway
[0138] The cGAS-STING signaling pathway plays an important role in host defense against pathogens, and STING agonists activate STING to produce IFN and other proinflammatory cytokines, such as TNFα and CXCL10. However, overactivation of this signaling pathway can lead to abnormal increases in type I interferon, TNFα, and CXCL10, which are associated with the development of many autoimmune diseases, such as rheumatoid arthritis and psoriasis. Therefore, the effects of compounds S11 and S12 of the present invention on downstream genes (IFN-β, TNFα, and CXCL10) of the STING signaling pathway were evaluated by real-time fluorescence quantitative PCR (qPCR), and the primer sequences of the detected genes are shown in Table 2.
[0139] In THP1 cells, the STING agonist SR717 treatment group was used as a control, and the DMSO group was used as a blank control. Different concentrations of compounds S11 and S12 (0.2 μM, 1.0 μM, 5.0 μM) were added to pretreat the cells for 1 hour, and then SR717 (20 μM) was added to activate the STING signaling pathway. After 4 hours, the cells were collected and RNA was extracted, and the gene expression of downstream inflammatory factors was determined by qPCR.
[0140] The experimental results are as follows Figure 6 As shown, compounds S11 and S12 of the present invention can inhibit the expression of downstream inflammatory factors caused by STING agonist SR717 in a dose-dependent manner. Under the action of 0.2 μM concentration of compounds S11 and S12, the inhibition effect is greater than 50%, and the upregulation of inflammatory factors caused by SR717 is almost completely inhibited at a concentration of 5 μM. The above results show that compounds S11 and S12 have the potential to treat inflammatory and autoimmune diseases.
[0141] Embodiment 22
[0142] Toxicity determination of compounds S11 and S12 of the present invention on normal cells
[0143] As anti-inflammatory drugs, the cytotoxicity of the compound to normal cells should not be too strong. Therefore, the cytotoxicity of S11, S12 and the positive control SN011 to HEK293T cells and RAW264.7 cells was measured to determine whether S11 and S12 were worth further development in terms of cytotoxicity.
[0144] Cells in the logarithmic growth phase were treated with DMSO and different concentrations of S11, S12 and SN011 for 24 hours, and the widely used MTT method was used to detect the inhibitory effects of the compounds on cell growth. Figure 7 As shown in the figure, the inhibition of cell growth by S11 and S12 was similar to that of the positive control SN011, and they showed slight growth inhibition activity starting from 30 μM. At 90 μM, more than 50% of the cells still survived. The above results show that the compounds S11 and S12 in the present invention have significant anti-inflammatory activity, while their cytotoxicity to normal cells HEK293T and RAW264.7 is not large, and the cytotoxic IC 50 The values were all greater than 90 μM, which showed high safety and was worthy of further research.
Claims
1. A thiourea compound or a pharmaceutically acceptable salt thereof, having a structure represented by formula (I): Formula (I) Wherein n=1-2, R1 is a chain alkyl group or an unsubstituted, monosubstituted or polysubstituted benzene ring, and R2 is an unsubstituted, monosubstituted or polysubstituted benzene ring or an unsubstituted thiophene ring; When R1 is a benzene ring and there is a substituent on the benzene ring, the substituent is selected from any one of halogen, cyano, trifluoromethyl, tert-butyl or methoxy; When R1 is a chain alkyl group, it is an alkane group with a length of 2-7; When R2 is a benzene ring and has a substituent, the substituent is selected from any one of halogen, nitro, trifluoromethyl and n-butyl.
2. The thiourea compound or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: The thiourea compound is specifically:
3. Use of the thiourea compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2 in the preparation of a STING inhibitor drug.
4. A STING inhibitor drug, characterized in that The thiourea compound or a pharmaceutically acceptable salt thereof is used to prepare the compound.
5. Use of the thiourea compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2 in the preparation of a medicament for preventing or treating a STING-mediated disease, characterized in that: The STING-mediated disease is selected from at least one of an infectious disease, an inflammatory disease, and an autoimmune disease.
6. A drug for preventing or treating a disease mediated by STING, characterized in that: It is prepared using the thiourea compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, and the STING-mediated disease is selected from at least one of infectious diseases, inflammatory diseases, and autoimmune diseases.
Citation Information
Patent Citations
Pyrrolopyrimidine derivative as well as preparation method and application thereof
CN115746026A
Methods of modulating immune activity
WO2020227159A2
